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Abstract
Although transcription activator-like effector nucleases (TALENs) can be designed to cleave 
chosen DNA sequences, TALENs have been shown to have activity against related off-target 
sequences. To better understand TALEN specificity and engineer TALENs with improved 
specificity, we profiled 30 unique TALENs with varying target sites, array length, and domain 
sequences for their ability to cleave any of 1012 potential off-target DNA sequences using in vitro 
selection and high-throughput sequencing. Computational analysis of the selection results 
predicted 76 off-target substrates in the human genome, 16 of which were accessible and modified 
by TALENs in human cells. The results collectively suggest that (i) TALE repeats bind DNA 
relatively independently; (ii) longer TALENs are more tolerant of mismatches, yet are more 
specific in a genomic context; and (iii) excessive DNA-binding energy can lead to reduced 
TALEN specificity in cells. Based on these findings, we engineered a TALEN variant, Q3, that 
exhibits equal on-target cleavage activity but 10-fold lower average off-target activity in human 
cells. Our results demonstrate that identifying and mutating residues that contribute to non-specific 
DNA-binding can yield genome editing reagents with improved DNA specificities.
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Introduction
The ability to engineer site-specific changes in genomes is a powerful capability with 
significant research and therapeutic implications. Transcription activator-like effector 
nucleases (TALENs) are fusions of the FokI restriction endonuclease cleavage domain with 
a DNA-binding TALE repeat array (Fig. 1A). These arrays consist of multiple 34-amino 
acid TALE repeat sequences, each of which uses a repeat-variable di-residue (RVD), the 
amino acids at positions 12 and 13, to recognize a single DNA nucleotide.1, 2 Examples of 
RVDs that recognize each of the four DNA base pairs are known, enabling arrays of TALE 
repeats to be constructed that can bind virtually any DNA sequence. TALENs can be 
engineered to be active only as heterodimers through the use of obligate heterodimeric FokI 
variants.3, 4 In this configuration, two distinct TALEN monomers are each designed to bind 
one target half-site resulting in cleavage within the DNA spacer sequence between the two 
half-sites. In cells, TALEN-induced double-strand breaks can result in targeted gene 
knockout through non-homologous end joining (NHEJ)5 or precise targeted genomic 
sequence alteration through homology-directed repair (HDR) with an exogenous DNA 
template.6, 7 TALENs have been successfully used to manipulate genomes in a variety of 
organisms6, 8–11 and cell lines.5, 7, 12, 13
Although TALENs are sufficiently specific to show activity against their intended target 
sites without causing widespread and highly abundant genomic off-target modification,14–17 
TALEN-mediated DNA cleavage at off-target sites can result in unintended mutations at 
genomic loci. While recent studies identify closely related off-target sites containing two or 
fewer mismatches in zebrafish18 and in human cell lines,13 more distantly related off-target 
sites are of particular interest since one would expect a typical 36-bp target site to be 
approximately eight or more mutations away from any sequence in the human genome. In 
previous studies, two distant genomic off-target sites were identified from 19 potential off-
target sites predicted using SELEX,7 an in vitro method to identify binding sites of DNA-
binding domains in isolation. Only a single heterodimeric off-target site was identified using 
an integrase-deficient lentiviral vector(IDLV)-based approach19, 20 to capture off-target 
double-strand break sites in cells. The limited number of off-target TALEN sites identified 
in previous studies suggest that further research is needed both to better understand the 
extent of TALEN-induced genomic off-target mutations and to improve TALEN specificity 
to minimize these unwanted effects.
The underlying principles that determine the specificities of TALEN proteins remain poorly 
characterized. While SELEX experiments and a high-throughput study of TALE activator 
specificity have described the DNA-binding specificities of monomeric TALE proteins5, 7,9 
and a single TALE activator,21 respectively, the DNA cleavage specificities of active, 
dimeric nucleases can differ from the specificities of their component monomeric DNA-
binding domains.22 For example, zinc finger nucleases (ZFNs), another type of engineered 
dimeric nuclease, demonstrate compensation effects between monomers.22 Cellular methods 
to study off-target genomic modification such as whole-genome sequencing or IDLV 
capture could be complicated by cellular factors such as DNA accessibility, which varies 
from site to site and between cell types,23 or DNA repair and integration pathways after 
cleavage that could obscure the determination of intrinsic TALEN protein specificity. Purely 
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cellular studies are also inherently limited to the stochastic handful of off-target sites in a 
given genome that are similar to the target sequence and thus are unable to evaluate the 
ability of TALENs to cleave a very large number of off-target sites necessary for a broad 
and in-depth study of TALEN specificity.
Using a previously described in vitro selection method,22, 24 we interrogated TALENs for 
their abilities to each cleave 1012 potential off-target DNA substrates related to their 
intended target sequences. The resulting data provide the first comprehensive profiles of 
TALEN cleavage specificities in a manner that is not limited to the small number of typical 
target-related sites in a genome. The selection results suggest a model in which excess non-
specific DNA-binding energy gives rise to greater off-target cleavage relative to on-target 
cleavage. Based on this model, we engineered TALENs with a modified architecture that 
show substantially improved DNA cleavage specificity in vitro. In human cells, these 
modified TALENs exhibit 24- to > 120-fold greater specificity for the most readily cleaved 
off-target site than currently used TALEN constructs.
Results
Specificity Profiling of TALENs targeting the human CCR5 and ATM genes
We profiled the specificities of 30 unique heterodimeric TALEN pairs (hereafter referred to 
as TALENs) harboring different C-terminal, N-terminal and FokI domain variants and 
targeted to sites with half-sites of various lengths. Throughout this report, the number of 
base pairs recognized by each half-site is listed to include the 5′ T nucleotide recognized by 
the N-terminal domain. Most of the TALENs tested contained the obligate heterodimeric 
EL/KK FokI domain, although the more active heterodimeric ELD/KKR and homodimeric 
FokI nuclease domain were also used, as specified below.3, 26 TALENs were constructed as 
previously reported12 and designed to target one of three distinct sequences, which we refer 
to as CCR5A, CCR5B, or ATM, in two different human genes, CCR5 and ATM 
(Supplementary Fig. S1). The specificity profiles were generated using a previously 
described in vitro selection method.22, 24 Briefly, pre-selection libraries of > 1012 DNA 
sequences each were digested with 3 nM to 40 nM of an in vitro-translated TALEN (see 
Methods and Supplementary Results for more detail). The pre-selection DNA libraries were 
sufficiently large that they each contain, in theory, at least ten copies of all possible DNA 
sequences with six or fewer mutations relative to the on-target sequence. Cleaved library 
members harbored a free 5′ monophosphate that enabled them to be captured by adapter 
ligation (Fig. 1B). DNA fragments of length corresponding to 1.5 target sites (an intact 
target site and a repeated half-site up to the point of TALEN-induced DNA cleavage) were 
isolated by gel purification. High-throughput sequencing and computational analysis of 
TALEN-treated or control samples surviving this selection process revealed the abundance 
of all TALEN-cleaved sequences as well as the abundance of the corresponding sequences 
before selection. In the control sample, all members of the pre-selection library were cleaved 
by a restriction endonuclease at a constant sequence to enable them to be captured by 
adapter ligation and isolated by gel purification. The enrichment value for each library 
member surviving selection was calculated by dividing its post-selection sequence 
abundance by its pre-selection abundance.
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For all TALEN variants and under all tested conditions, the DNA that survived the selection 
contained significantly fewer mean mutations in the targeted half-sites than were present in 
the preselection libraries (Fig. 2A and 2B; Supplementary Table S2 and S3). For all 
selections, the on-target sequences were enriched by 8- to 640-fold with an average 
enrichment value of 110-fold (Supplementary Table S4). To validate our selection results in 
vitro, we assayed the ability of the CCR5B TALEN targeting 13-bp left and right half-sites 
(L13+R13) to cleave each of 16 diverse off-target substrates (Fig. 2E and 2F). The 
efficiencies with which each of these 16 putative off-target substrates were cleaved by the 
TALEN in these discrete in vitro assays correlated well (r = 0.90) with the observed 
enrichment values from the selection (Fig. 2G).
To quantify the DNA cleavage specificity at each position in the TALEN target site for all 
four possible base pairs, a specificity score was calculated as the difference between pre-
selection and post-selection base pair frequencies, normalized to the maximum possible 
change of the pre-selection frequency from complete specificity (defined as 1.0) to complete 
anti-specificity (defined as −1.0). For all TALENs tested, the targeted base pair at every 
position in both half-sites is preferred, with the sole exception of the base pair closest to the 
spacer for some ATM TALENs at the right-half site (Fig. 2C, 2D and Supplementary Fig. 
S3 through S8). The 5′ T recognized by the N-terminal domain is highly specified, and the 
3′ DNA end (targeted by the C-terminal TALEN end) generally tolerates more mutations 
than the 5′ DNA end; both of these observations are consistent with previous reports.27, 28 
All 12 of the positions targeted by the NN RVDs in the ATM and CCR5A TALENs were 
enriched for G, confirming previous reports5, 7, 27, 29 that the NN RVD specifies G. Taken 
together, these results show that the selection data accurately predicts the efficiency of off-
target TALEN cleavage in vitro, and that TALENs are overall quite specific across the entire 
target sequence.
TALEN Off-Target Cleavage in Cells
For TALENs targeting a total of 36 base pairs, potential off-target sites in the human 
genome are expected on average to contain approximately eight or more mutations relative 
to the on-target site (Supplementary Table S5), more mutations than theoretically are 
covered in the in vitro selection. Therefore, we used a machine-learning “classifier” 
algorithm25 trained on the tens of thousands of off-target sites revealed by the in vitro 
selection to identify rare TALEN candidate off-target sites in the human genome (see 
Supplementary Results for details). Using this algorithm, we identified the 36 best-scoring 
heterodimeric candidate off-target sites for the ATM TALENs and 48 of the best-scoring 
candidate off-target sites for the CCR5A TALENs (Supplementary Table S6). These sites 
differ from the on-target sequence at seven to fourteen positions.
These 84 predicted off-target sites for CCR5A and ATM TALENs were amplified from 
genomic DNA purified from human U2OS-EGFP cells expressing either CCR5A or ATM 
TALENs.12 Sequences containing insertions or deletions of three or more base pairs in the 
DNA spacer of the potential genomic off-target sites and present in significantly greater 
numbers in the TALEN-treated samples versus the untreated control sample were considered 
TALEN-induced modifications. Consistent with a previous report3, CCR5A or ATM 
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TALENs containing ELD/KKR and homodimeric FokI domains demonstrated increased on-
target activity compared to EL/KK FokI domains. Of the 45 CCR5A off-target sites that we 
successfully amplified, we identified nine off-target sites with TALEN-induced 
modifications; likewise, of the 31 ATM off-target sites that we successfully amplified, we 
observed seven off-target sites with TALEN-induced modifications (Fig. 3 and 
Supplementary Table S7 and S9). Therefore, in total, 16 out of 76 assayed off-target 
candidates were accessible and modified by TALENs in cells. The inspection of modified 
on-target and off-target sites yielded a prevalence of deletions ranging from three to dozens 
of base pairs (Supplementary Fig. S9), consistent with previously described characteristics 
of TALEN-induced genomic modification.31 These results collectively indicate in vitro 
selection data processed through a machine-learning algorithm, can predict bona fide off-
target substrates that undergo TALEN-induced modification in human cells. We also 
directly compared our combined in vitro selection and machine learning method with 
TALENoffer, a recently described purely computational prediction method32 and found that 
our approach outperforms the purely computational approach for the identification of 
TALEN-induced off-target substrates in cells (Supplementary Tables S8 and S9 and 
Supplementary Results).
TALE Repeat Binding Independence and Effects of TALEN Length on Specificity
The extensive number of quantitatively characterized off-target substrates in the selection 
data enabled us to address several key questions about TALEN specificity. First, we 
assessed whether mutations at one position in the target sequence affect the ability of 
TALEN repeats to productively bind other positions and concluded that TALE repeats bind 
their respective DNA base pairs independently beyond a slightly increased tolerance for 
adjacent mismatches (Supplementary Results).
The independent binding of TALE repeats simplistically predicts that TALEN specificity 
per base pair is independent of target-site length. To experimentally characterize the 
relationship between TALE array length and off-target cleavage, we constructed TALENs 
targeting 10, 13, or 16 bps (including the 5′ T) for both the left (L10, L13, L16) and right 
(R10, R13, R16) half-sites. TALENs representing all nine possible combinations of left and 
right CCR5B TALENs were subjected to in vitro selection. The results revealed that shorter 
TALENs have greater specificity per targeted base pair than longer TALENs 
(Supplementary Table S2). For example, sequences cleaved by the L10+R10 TALEN 
contained a mean of 0.032 mutations per recognized base pair, while those cleaved by the 
L16+R16 TALEN contained a mean of 0.067 mutations per recognized base pair.
For selections with the longest CCR5B TALENs targeting 16+16 base pairs or CCR5A and 
ATM TALENs targeting 18+18 bp, the mean selection enrichment values do not follow a 
simple exponential decrease as function of mutation number (Fig. 4 and Supplementary 
Table S10). It is possible these TALENs have greater affinity than is required to 
substantially bind and cleave the target site (referred to hereafter as “excess DNA-binding 
energy”). Thus, we hypothesize that excess DNA-binding energy from the larger number of 
TALE repeats in longer TALENs reduces specificity by enabling the cleavage of sequences 
with more mutations, without a corresponding increase in the cleavage of sequences with 
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fewer mutations, because the latter are already nearly completely cleaved. Indeed, the in 
vitro cleavage efficiencies of discrete DNA sequences for these longer TALENs are 
independent of the presence of a small number of mutations in the target site (Fig. 5C–5F), 
suggesting there is nearly complete binding and cleavage of sequences containing few 
mutations. Likewise, higher TALEN concentrations also result in decreased enrichment 
values of sequences with few mutations while increasing the enrichment values of sequences 
with many mutations (Supplementary Table S4). These results together support a model in 
which excessive TALEN binding arising from either long TALE arrays or high TALEN 
concentrations decreases the observed TALEN DNA cleavage specificity for each 
recognized base pair. Despite being less specific per base pair, TALENs designed to cleave 
longer target sites are estimated to have higher overall specificity than those that target 
shorter sites when considering the number of potential off-target sites in the human genome 
(Supplementary Results).
Engineering TALENs with Improved Specificity
The findings above suggest that TALEN specificity could be improved by reducing non-
specific DNA binding energy to only what is needed to support efficient on-target cleavage. 
The most widely used 63-aa C-terminal domain between the TALE repeat array and the 
FokI nuclease domain contains ten cationic residues.4, 5, 7, 9, 10, 12 A related C-terminal 
domain variant (89% homology), containing 11 cationic residues, has also been used in 
other studies.6, 20, 28 We hypothesized that reducing the cationic charge of the canonical 63-
aa TALE C-terminal domain would decrease non-specific DNA binding33 and improve the 
specificity of TALENs.
We constructed two C-terminal domain variants in which three (“Q3”, consisting of K788Q, 
R792Q, and R801Q) or seven (“Q7”, consisting of K777Q, K778Q, K788Q, R789Q, 
R792Q, R793Q, and R801Q) cationic Arg or Lys residues in the canonical 63-aa C-terminal 
domain were mutated to Gln. We performed in vitro selections on CCR5A and ATM 
TALENs containing the canonical 63-aa, the engineered Q3, and the engineered Q7 C-
terminal domains, as well as a previously reported 28-aa truncated C-terminal domain5 with 
a theoretical net charge (−1) identical to that of the Q7 C-terminal domain. The on-target 
sequence enrichment values for the CCR5A and ATM selections increased substantially as 
the net charge of the C-terminal domain decreased (Fig. 5A and 5B). For example, the ATM 
selections resulted in on-target enrichment values of 510, 50, and 20 for the Q7, Q3, and 
canonical 63-aa C-terminal variants, respectively. These results suggest that the TALEN 
variants in which cationic residues in the C-terminal domain have been partially replaced by 
neutral residues or completely removed are substantially more specific in vitro than the 
TALENs that contain the canonical, commonly used 63-aa C-terminal domain. Similarly, 
mutating one, two, or three cationic residues in the TALEN N-terminus to Gln also 
increased cleavage specificity (Supplementary Table S4, and Supplementary Fig. S3–S6, 
and see Supplementary Results).
In order to confirm the greater DNA cleavage specificity of Q7 over canonical 63-aa C-
terminal domains in vitro, a representative set of 16 off-target DNA substrates was digested 
in vitro with TALENs containing either canonical 63-aa or engineered Q7 C-terminal 
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domains. ATM TALENs with the canonical 63-aa C-terminal domain demonstrated 
comparable in vitro cleavage activity on target sites with zero, one, or two mutations (Fig. 
5C–5F). CCR5A TALENs with the canonical 63-aa C-terminal domain TALEN 
demonstrate comparable in vitro cleavage activity on target sites with zero or two mutations. 
In contrast, for 11 of the 16 off-target substrates tested, the engineered Q7 TALEN variants 
showed substantially higher (~4-fold or greater) discrimination against off-target DNA 
substrates with one or two mutations than the canonical 63-aa C-terminal domain TALENs, 
even though the Q7 TALENs cleaved their respective on-target sequences in vitro with 
comparable or greater efficiency than TALENs with the canonical 63-aa C-terminal domains 
(Fig. 5C–5F). For both the ATM and CCR5A Q7 C-terminal TALENs, some sequences are 
cleaved with greater specificity than others. Sequence-dependent specificity is expected 
based on the variable specificity at each position (Fig. 2C and D). Overall, the discrete 
cleavage assays are consistent with the selection results and indicate that TALENs with 
engineered Q3 or Q7 C-terminal domains can be substantially more specific than TALENs 
with canonical 63-aa C-terminal domains in vitro.
Improved Specificity of Engineered TALENs in Human Cells
To determine if the increased specificity of the engineered TALENs observed in vitro also 
occurs in human cells, TALEN-induced modification rates of the on-target and top 36 
predicted off-target sites were measured for CCR5A and ATM TALENs containing all six 
possible combinations of the canonical 63-aa, Q3, or Q7 C-terminal domains and the EL/KK 
or ELD/KKR FokI domains (12 TALENs total). We did not analyze TALENs containing a 
28-aa C-terminal domain in these experiments because both the ATM and CCR5A on-target 
sites have DNA spacer lengths of 18 bp, which lies outside the 28-aa C-terminal domain’s 
preferred DNA spacer length range (Supplementary Fig. S14). For both FokI variants, the 
TALENs with Q3 C-terminal domains demonstrate significant on-target activities ranging 
from 8% to 24% modification, comparable to the activity of TALENs with the canonical 63-
aa C-terminal domains. TALENs with canonical 63-aa or Q3 C-terminal domains and the 
ELD/KKR FokI domain are both more active in modifying the CCR5A and ATM on-target 
site in cells than the corresponding TALENs with the Q7 C-terminal domain by 5- to 9-fold 
(Fig. 6A–C and Supplementary Table S7).
Compared to the canonical 63-aa C-terminal domains, TALENs with Q3 C-terminal 
domains demonstrate a mean increase in on-target:off-target activity ratio of more than 12-
fold and more than 9-fold for CCR5A and ATM sites, respectively, with the ELD/KKR FokI 
domain (Fig. 6A–C & Supplementary Table S7). These mean improvements can only be 
expressed as lower limits due to the absence or near-absence of observed cleavage events by 
the engineered TALENs for many off-target sequences. For the ATM TALENs containing 
Q7 C-terminal domains, the cleavage efficiency of both the on-target and off-target sites is 
so low that their specificity cannot be determined (Fig. 6C). For the most abundantly 
cleaved off-target site (CCR5A off-target site #5), the Q3 C-terminal domain is 24-fold 
more specific, and the Q7 C-terminal domain is > 120-fold more specific (Fig. 6A), than the 
canonical 63-aa C-terminal domain. Consistent with the improved on-target:off-target 
activity ratio observed in vitro, the engineered Q7 TALENs are more specific than the Q3 
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variants, which in turn are more specific than the canonical 63-aa C-terminal domain 
TALENs.
To determine if the increased specificity of the engineered TALENs observed for CCR5A 
and ATM TALENs applies more generally, three new TALENs targeting sequences in the 
PMS2, SDHD, and HDAC1 genes12 were constructed using the canonical 63-aa, Q3, or Q7 
C-terminal domains and ELD/KKR FokI domains. Of the 64 TALENs reported previously 
in Reyon et al, these three TALENs had target sequences with closely homologous genomic 
off-target sites containing one to five mutations. For each of these TALENs, modification 
rates were measured for genomic on-target and off-target sites. PMS2, SDHD, and HDAC-1 
TALENs with Q3 C-terminal domains demonstrate on-target activities ranging from 6% to 
28% modification, comparable to the activity of TALENs with the canonical 63-aa C-
terminal domains (Fig. 6D and Supplementary Table S8). While demonstrating similar on-
target activities to TALENs with canonical domains, PMS2, SDHD, and HDAC1 TALENs 
with Q3 C-terminal domains demonstrated a 5- to 7-fold increase in on-target:off-target 
activity ratio. For the PMS2 TALENs, the Q7 C-terminal domains demonstrated a 53- and 
64-fold increase in on-target:off-target activity ratio in cells, although as observed above the 
Q7 TALENs were less active on the target site than TALENs containing the canonical and 
Q3 C-terminal domains (Fig. 6D and Supplementary Table S8).
Together, these results reveal that for five families of TALENs targeting the CCR5, ATM, 
PMS2, SDHD, and HDAC1 genes, replacing the canonical 63-aa C-terminal domain with 
the engineered Q3 C-terminal domain results in comparable activity for the on-target site in 
cells, and an average 10-fold increase in specificity for all assayed off-target sites. The 
engineered Q7 C-terminal domain can offer additional gains in specificity beyond that of the 
Q3 TALENs, but with reduced on-target activity. Collectively, these results validate a 
method to evaluate the specificity of TALEN variants that also revealed underlying 
principles resulting in engineered TALENs with improved DNA cleavage specificity in 
cells.
Discussion
The in vitro selection results for 30 unique TALENs each challenged with 1012 closed 
related off-target sequences and subsequent analysis inform our understanding of TALEN 
specificity through four key findings: (i) TALENs are highly specific for their intended 
target base pair at 103 of the 104 positions profiled with specificity increasing near the N-
terminal TALEN end of each TALE repeat array (corresponding to the 5′ end of the bound 
DNA); (ii) longer TALENs are more specific in a genomic context while shorter TALENs 
have higher specificity per nucleotide; (iii) TALE repeats each bind their respective base 
pairs relatively independently; and (iv) excess DNA-binding affinity leads to increased 
TALEN activity against off-target sites and therefore decreased specificity.
The 16 confirmed TALEN off-target sites containing eight to 12 mutations identified from 
the 76 predicted sites assayed in this study represent more bona fide genomic off-target sites 
in the human genome than have been revealed collectively to date by other methods. These 
16 sites were modified at efficiencies ranging from 2.3% to 0.03% in human cells, 
Guilinger et al. Page 8
Nat Methods. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
demonstrating that TALENs can have appreciable off-target activities in human cells even at 
sites that are eight or more mutations away from the on-target sequence. Site accessibility in 
cells, mediated by histone proteins, transcription factors, and DNA modification,23 likely 
account for at least some of the difference between our in vitro, computational, and cell-
based results. For a comparison of our method with others for characterizing TALEN 
specificity and identifying genomic TALEN off-target sites, see the Supplementary 
Discussion.
The observed decrease in specificity for TALENs with more TALE repeats or more cationic 
residues in the C-terminal domain or N-terminus are consistent with a model in which 
excess TALEN binding affinity leads to increased promiscuity. This excess binding energy 
model may explain reports that NN RVDs bind either A or G.2,28,35 These studies used 
TALE arrays of more than 14 RVDs, which could have created a scenario in which excess 
DNA-binding energy permits a suboptimal NN RVD interaction with A compared to G. We 
observed NN RVDs can discriminate between A and G, consistent with reports using shorter 
TALE arrays of 13 RVDs29 and by direct biochemical interrogation.27 Excess DNA-binding 
energy could also explain the previously reported promiscuity at the 5′ terminal T of 
TALENs with longer C-terminal domains36 and is consistent with a report of higher TALEN 
protein concentrations resulting in more off-target site cleavage in vivo.9 While decreasing 
TALEN protein expression in cells in theory could reduce off-target cleavage, TALE arrays 
are reported with on-target DNA binding affinities as high as Kd = 2.8 nM,27 which is 
sufficient to theoretically saturate target sites even when expressed at modest, mid-nM 
concentrations in the cell. The difficulty of improving the specificity of such TALENs by 
lowering their expression levels, coupled with the need to maintain sufficient TALEN 
concentrations to effect desired levels of on-target cleavage, highlight the value of 
engineering TALENs with higher intrinsic specificity such as those described in this work.
Our findings suggest that mutant C-terminal domains with reduced non-specific DNA 
binding may be used to alter the DNA-binding affinity of TALENs such that on-target 
sequences are cleaved efficiently but with minimal excess DNA-binding energy, resulting in 
better discrimination between on-target and off-target sites. Since TALENs targeting up to 
46 total base pairs have been shown to be active in cells,14 it may be possible to further 
improve specificity by engineering TALENs with a combination of mutant N-terminal and 
C-terminal domains that impart reduced non-specific DNA-binding, a greater number of 
TALE repeats to contribute additional on-target DNA binding, and lower-affinity RVDs 
such as the NK RVD to recognize G.28, 29 It is tempting to speculate that the strategy of 
mutating residues that contribute to non-specific DNA binding to improve DNA specificity 
may also apply to other genome engineering proteins including Cas9 and ZFNs.
Our model and the resulting improved TALENs would have been difficult to derive or 
validate using purely cellular off-target cleavage methods. The ability of our profiling 
method to reveal the broad, unobscured DNA cleavage specificity of TALENs in the 
absence of cellular complications enabled the elucidation of the inherent DNA-cleavage 
specificity of TALENs. Studies of cellular off-target cleavage are also intrinsically limited 
by the small number of sequences present in a genome that may be closely related to a target 
sequence of interest. In contrast, each active, dimeric TALEN in this study was evaluated for 
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its ability to cleave any of 1012 close variants of its on-target sequence, a library size several 
orders of magnitude greater than the number of different sequences in a mammalian 
genome. This dense coverage of off-target sequence space enabled the elucidation of 
detailed relationships between DNA-cleavage specificity and target base pair position, 
TALE repeat length, TALEN concentration, mismatch location, and engineered TALEN 
composition. These results collectively reveal principles for characterizing and improving 
TALENs with greater specificity that may enable a wider range of genome engineering 
applications.
ONLINE METHODS
Oligonucleotides, PCR and DNA Purification
All oligonucleotides were purchased from Integrated DNA Technologies (IDT). 
Oligonucleotide sequences are listed in Supplementary Table S12. PCR was performed with 
0.4 μL of 2 U/μL Phusion Hot Start II DNA polymerase (Thermo-Fisher) in 50 μL with 1x 
HF Buffer, 0.2 mM dNTP mix (0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM 
dTTP) (NEB), 0.5 μM to 1 μM of each primer and a program of: 98 °C, 1 min; 35 cycles of 
[98 °C, 15 s; 62 °C, 15 s; 72 °C, 1 min] unless otherwise noted. Many DNA reactions were 
purified with a QIAquick PCR Purification Kit (Qiagen) referred to below as Q-column 
purification or MinElute PCR Purification Kit (Qiagen) referred to below as M-column 
purification.
TALEN Construction
The canonical TALEN plasmids were constructed by the FLASH method12 with each 
TALEN targeting 10–18 base pairs. N-terminal mutations were cloned by PCR with Q5 Hot 
Start Master Mix (NEB) [98 °C, 22 s; 62 °C, 15 s; 72 °C, 7 min]) using phosphorylated 
TAL-N1fwd (for N1), phosphorylated TAL-N2fwd (for N2), or phosphorylated TAL-N3fwd 
(for N3) and phosphorylated TAL-Nrev as primers. 1 μL DpnI (NEB) was added and the 
reaction was incubated at 37 °C for 30 min then M-column purified. ~25 ng of eluted DNA 
was blunt-end ligated intramolecularly in 10 μL 2x Quick Ligase Buffer, 1 μL of Quick 
Ligase (NEB) in a total volume of 20 μL at room temperature (~21 °C) for 15 min. 1 μL of 
this ligation reaction was transformed into Top10 chemically competent cells (Invitrogen). 
C-terminal domain mutations were cloned by PCR using TAL-Cifwd and TAL-Cirev 
primers, then Q-column purified. ~1 ng of this eluted DNA was used as the template for 
PCR with TAL-Cifwd and either TAL-Q3 (for Q3) or TAL-Q7 (for Q7) for primers, then Q-
column purified. ~1 ng of this eluted DNA was used as the template for PCR with TAL-
Cifwd and TAL-Ciirev for primers, then Q-column purified. ~1 μg of this DNA fragment 
was digested with HpaI and BamHI in 1x NEBuffer 4 and cloned22 into ~2 μg of desired 
TALEN plasmid pre-digested with HpaI and BamHI. TALENs containing the N-terminal 
mutant domains, the Q3 C-terminal domains and the Q7 C-terminal will be available from 
Addgene.
In Vitro TALEN Expression
TALEN proteins, all containing a 3xFLAG tag, were expressed by in vitro transcription/
translation. 800 ng of TALEN-encoding plasmid or no plasmid (“empty lysate” control) was 
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added to an in vitro transcription/translation reaction using the TNT® Quick Coupled 
Transcription/Translation System, T7 Variant (Promega) in a final volume of 20 μL at 30 °C 
for 1.5 h. Western blots were used to visualize protein using the anti-FLAG M2 monoclonal 
antibody (Sigma-Aldrich). TALEN concentrations were calculated by comparison to 
standard curve of 1 ng to 16 ng N-terminally FLAG-tagged bacterial alkaline phosphatase 
(Sigma-Aldrich).
In Vitro Selection for DNA Cleavage
Pre-selection libraries were prepared with 10 pmol of oligo libraries containing partially 
randomized target half-site sequences (CCR5A, ATM, or CCR5B) and fully randomized 10- 
to 24-bp spacer sequences (Supplementary Table S12). Oligonucleotide libraries were 
separately circularized by incubation with 100 units of CircLigase II ssDNA Ligase 
(Epicentre) in 1x CircLigase II Reaction Buffer (33 mM Tris-acetate, 66 mM potassium 
acetate, 0.5 mM dithiothreitol, pH 7.5) supplemented with 2.5 mM MnCl2 in 20 μL total for 
16 h at 60 °C then incubated at 80 °C for 10 min. 2.5 μL of each circularization reaction was 
used as a substrate for rolling-circle amplification at 30 °C for 16 h in a 50-μL reaction using 
the Illustra TempliPhi 100 Amplification Kit (GE Healthcare). The resulting concatemerized 
libraries were quantified with Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen) and 
libraries with different spacer lengths were combined in an equimolar ratio.
For selections on the CCR5B sequence libraries, 500 ng of pre-selection library was 
digested for 2 h at 37 °C in 1x NEBuffer 3 with in vitro transcribed/translated TALEN plus 
empty lysate (30 μL total). For all CCR5B TALENs, in vitro transcribed/translated TALEN 
concentrations were quantified by Western blot (during the blot, TALENs were stored for 16 
h at 4 °C) and then TALEN was added to 40 nM final concentration per monomer. For 
selections on CCR5A and ATM sequence libraries, the combined pre-selection library was 
further purified in a 300,000 MWCO spin column (Sartorius) with three 500-μL washes in 
1x NEBuffer 3. 125 ng pre-selection library was digested for 30 min at 37 °C in 1x 
NEBuffer 3 with a total 24 μL of fresh in vitro transcribed/translated TALENs and empty 
lysate. For all CCR5A and ATM TALENs, 6 μL of in vitro transcription/translation left 
TALEN and 6 μL of right TALEN were used, corresponding to a final concentration in a 
cleavage reaction of 16 nM ± 2 nM or 12 nM ± 1.5 nM for CC5A or ATM TALENs, 
respectively. These TALEN concentrations were quantified by Western blot performed in 
parallel with digestion.
For all selections, the TALEN-digested library was incubated with 1 μL of 100 μg/μL RNase 
A (Qiagen) for 2 min and then Q-column purified. 50 μL of purified DNA was incubated 
with 3 μL of 10 mM dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM dTTP) 
(NEB), 6 μL of 10x NEBuffer 2, and 1 μL of 5 U/μL Klenow Fragment DNA Polymerase 
(NEB) for 30 min at room temperature and Q-column purified. 50 μL of the eluted DNA 
was ligated with 2 pmol of heated and cooled #1 adapters containing barcodes 
corresponding to each sample (selections with different TALEN concentrations or 
constructs) (Supplementary Table S12A). Ligation was performed in 1x T4 DNA Ligase 
Buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, pH 7.5) with 1 μL of 
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400 U/μL T4 DNA ligase (NEB) in 60 μL total volume for 16 h at room temperature, then 
Q-column purified.
6 μL of the eluted DNA was amplified by PCR in 150 μL total reaction volume (divided into 
3x 50 μL reactions) for 14 to 22 cycles using the #2A adapter primers in Supplementary 
Table S12A. The PCR products were purified by Q-column. Each DNA sample was 
quantified with Quant-iT™ PicoGreen® dsDNA Kit (Invitrogen) and then pooled into an 
equimolar mixture. 500 ng of pooled DNA was run a 5% TBE 18-well Criterion PAGE gel 
(BioRad) for 30 min at 200 V and DNAs of length ~230 bp (corresponding to 1.5 target site 
repeats plus adapter sequences) were isolated and purified by Q-column. ~2 ng of eluted 
DNA was amplified by PCR for 5 to 8 cycles with #2B adapter primers (Supplementary 
Table S12A) and purified by M-column.
10 μL of eluted DNA was purified using 12 μL of AMPure XP beads (Agencourt) and 
quantified with an Illumina/Universal Library Quantification Kit (Kapa Biosystems). DNA 
was prepared for high-throughput DNA sequencing according to Illumina instructions and 
sequenced using a MiSeq DNA Sequencer (Illumina) using a 12 pM final solution and 156-
bp paired-end reads. To prepare the preselection library for sequencing, the pre-selection 
library was digested with 1 μL to 4 μL of appropriate restriction enzyme (CCR5A = Tsp45I, 
ATM = Acc65I, CCR5B = AvaI (NEB)) for 1 h at 37 °C then ligated as described above 
with 2 pmol of heated and cooled #1 library adapters (Supplementary Table S9A). Pre-
selection library DNA was prepared as described above using #2A library adapter primers 
and #2B library adapter primers in place of #2A adapter primers and #2B adapter primers, 
respectively (Supplementary Table S12A). The resulting pre-selection library DNA was 
sequenced together with the TALEN-digested samples.
Discrete In Vitro TALEN Cleavage Assays
Discrete DNA substrates for TALEN digestion were constructed by combining pairs of 
oligonucleotides as specified in Supplementary Table 12B with restriction cloning22 into 
pUC19 (NEB). Corresponding cloned plasmids were amplified by PCR (59 °C annealing for 
15 s) for 24 cycles with pUC19Ofwd and pUC19Orev primers (Supplementary Table S12B) 
and Q-column purified. 50 ng of amplified DNAs were digested in 1x NEBuffer 3 with 3 μL 
each of in vitro transcribed/translated TALEN left and right monomers (corresponding to a 
~16 nM to ~12 nM final TALEN concentration), and 6 μL of empty lysate in a total reaction 
volume of 120 μL. The digestion reaction was incubated for 30 min at 37 °C, then incubated 
with 1 μL of 100 μg/μL RNase A (Qiagen) for 2 min and purified by M-column. The entire 
10 μL of eluted DNA with glycerol added to 15% was analyzed on a 5% TBE 18-well 
Criterion PAGE gel (Bio-Rad) for 45 min at 200 V, then stained with 1x SYBR Gold 
(Invitrogen) for 10 min. Bands were visualized and quantified on an AlphaImager HP 
(Alpha Innotech).
Cellular TALEN Cleavage Assays
TALENs were cloned into mammalian expression vectors12 and the resulting TALEN 
vectors transfected into U2OS-EGFP cells as previously described.12 Genomic DNA was 
isolated after 2 days as previously described.12 For each assay, 50 ng of isolated genomic 
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DNA was amplified by PCR [98 °C, 15 s 67.5 °C, 15 s; 72 °C, 22s] for 35 cycles with pairs 
of primers with or without 4% DMSO as specified in Supplementary Table S12C. Two PCR 
reactions were performed for OffC-5 to improve the limit of detection. The relative dsDNA 
content of the PCR reaction for each genomic site was quantified with Quant-iT™ 
PicoGreen ® dsDNA Kit (Invitrogen) and then pooled into an equimolar mixture, keeping 
no-TALEN and all TALEN-treated samples separate. DNA corresponding to 150 to 350 bp 
was purified by PAGE as described above.
44 μL of eluted DNA was incubated with 5 μL of 1x T4 DNA Ligase Buffer and 1 μL of 10 
U/μL Polynucleotide kinase (NEB) for 30 min at 37 °C and Q-column purified. 43 μL of 
eluted DNA was incubated with 1 μL of 10 mM dATP (NEB), 5 μL of 10x NEBuffer 2, and 
1 μL of 5 U/μL DNA Klenow Fragment (3′ → 5′ exo−) (NEB) for 30 min at 37 °C and 
purified by M-column. 10μL of eluted DNA was ligated as above with 10 pmol of heated 
and cooled G (genomic) adapters (Supplementary Table S12A) and purified by Q-column. 8 
μL of eluted DNA was amplified by PCR for 6 to 8 cycles with G-B primers containing 
barcodes corresponding to each sample. Each sample DNA was quantified with Quant-iT™ 
PicoGreen ® dsDNA Kit (Invitrogen) and then pooled into an equimolar mixture. The 
combined DNA was subjected to high-throughput sequencing using a MiSeq as described 
above.
Data Analysis
Illumina sequencing reads were filtered and parsed with scripts written in Unix Bash as 
outlined in the Supplementary Algorithms. DNA sequences and source code are available 
upon request. Specificity scores were calculated as previously described.22 Sample sizes for 
sequencing experiments were maximized (within practical experimental considerations) to 
ensure greatest power to detect effects. Statistical analysis on the distribution of number of 
mutations in various TALEN selections in Supplementary Table S2 was performed as 
previously described22. Statistical analysis of TALEN modified genomic sites in 
Supplementary Tables S7, S8 and S9 was performed as previously described25 with multiple 
comparison correction using the Benjamini-Hochberg method.37, 38
To determine extrapolated mean enrichment curves mutation enrichment value as function 
of mutation number were fit to an exponential function, a*eb, with R2 reported utilizing the 
non-linear least squares method. The a, b and R2 values and the mutation range for these fits 
are reported in Supplementary Table S11. These exponential decrease, b, were used to 
extrapolate all mean enrichment values beyond five mutations to determine the extrapolated 
mean enrichment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TALEN architecture and selection scheme
(A) Architecture of a TALEN. A TALEN monomer contains an N-terminal domain (blue) 
followed by an array of TALE repeats (brown), a C-terminal domain (green), and a FokI 
nuclease cleavage domain (purple). The 12th and 13th amino acids (the RVD, red) of each 
TALE repeat recognize a specific DNA base pair. Two different TALENs bind their 
corresponding half-sites, allowing FokI dimerization and DNA cleavage. The C-terminal 
domain variants used in this study are shown in green. (B) A single-stranded library of DNA 
oligonucleotides containing partially randomized left half-site (L), spacer (S), right half-site 
(R) and constant region (thick black line) was circularized, then concatemerized by rolling 
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circle amplification. The concatemerized double stranded DNA (double arrows) contained 
repeated target sites with L′ S′ R′ representing the reverse sequence complement of L S R. 
(C) The concatemerized DNA libraries of mutant target sites were incubated with an in 
vitro-translated TALEN of interest. Cleaved library members were blunted and ligated to 
adapter #1. The ligation products were amplified by PCR using one primer consisting of 
adapter #1 and the other primer consisting of adapter #2–constant sequence, which anneals 
to the constant regions. From the resulting ladder of amplicons containing a half-site with an 
integral number (n) of repeats of a target site (represented by brackets), amplicons 
corresponding to 1.5 target-sites in length were isolated by gel purification and subjected to 
high-throughput DNA sequencing and computational analysis (Supplementary Algorithms).
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Figure 2. In vitro selection results
The fraction of sequences surviving selection (green) and before selection (black) are shown 
for CCR5A TALENs (A) and ATM TALENs (B) with EL/KK FokI domains as a function 
of the number of mutations in both half-sites (left and right half-sites combined excluding 
the spacer). (C) Specificity scores for the CCR5A TALENs at all positions in the target half-
sites plus a single flanking position. The colors range from dark blue (maximum specificity 
score of 1.0) to white (no specificity, score of 0) to dark red (maximum negative score of 
−1.0); see the main text for details. Boxed bases represent the intended target base. Note for 
the right half-site, the R18 TALENs, the sense strand is shown. (D) Same as (C) for the 
ATM TALENs. For (A), (B), (C) and (D) sample statistics (sample sizes, means, standard 
deviations, and P-values) are given in Supplementary Table S2 and S3. (E) Enrichment 
values from the selection of L13+R13 CCR5B TALEN for 16 mutant DNA sequences 
(mutations in red) relative to on-target DNA (OnB). (F) Correspondence between discrete in 
vitro TALEN cleavage efficiency (cleaved DNA as a fraction of total DNA) for the 
sequences listed in (E) normalized to on-target cleavage (= 1) versus their enrichment values 
in the selection normalized to the on-target enrichment value (= 1). The Pearson’s r 
coefficient of correlation between normalized cleavage efficiency and normalized 
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enrichment value is 0.90. (G) Discrete assays of on-target and off-target sequences used in 
(F) as analyzed by PAGE.
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Figure 3. Cellular modification induced by TALENs at on-target and predicted off-target 
genomic sites
(A) For cells treated with either no TALEN or CCR5A TALENs containing heterodimeric 
EL/KK, heterodimeric ELD/KKR, or the homodimeric (Homo) FokI cleavage domain 
variants, cellular modification rates are shown as the percentage of observed insertions or 
deletions (indels) consistent with TALEN cleavage relative to the total number of sequences 
for on-target (On) and predicted off-target sites (Off). See the main text for details. ND 
refers to no data collected since the cellular modification of off-target sites OffC-38, 
OffC-49, OffC-69 and OffC-76 was not assayed for CCR5A TALENs containing EL/KK 
and ELD/KKR FokI domains. (B) Same as (A) for ATM TALENs. For (A) and (B) sample 
sizes and P-values are given in Supplementary Tables S7 and S9.
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Figure 4. In vitro specificity as a function of TALEN length
The enrichment value of on-target (zero mutation) and off-target sequences containing one 
to six mutations are shown for CCR5B TALENs of varying TALE repeat array lengths with 
EL/KK FokI domains. The TALENs targeted DNA sites of 32 bp (L16+R16), 29 bp 
(L16+R13 or L13+R16), 26 bp (L16+R10 or L13+R13 or L10+R16), 23 bp (L13+R10 or 
L10+R13) or 20 bp (L10+R10) in length.
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Figure 5. In vitro specificity and discrete cleavage efficiencies of TALENs containing canonical or 
engineered C-terminal domains
(A and B) On-target enrichment values for selections of (A) CCR5A TALENs containing 
canonical, Q3, Q7, or 28-aa C-terminal domains with EL/KK FokI cleavage domains or (B) 
ATM TALENs containing canonical, Q3 or Q7 C-terminal domains with EL/KK FokI 
cleavage domains. (C) CCR5A on-target sequence (OnC) and double-mutant sequences with 
mutations in red. For CCR5A, sequences containing two mutations were assayed because 
one-mutation and zero-mutation sequences were similarly enriched (Supplementary Table 
S4A). (D) ATM on-target sequence (OnA), single-mutant sequences, and double-mutant 
sequences with mutations in red. (E) Discrete in vitro cleavage efficiency of DNA sequences 
listed in (C) with CCR5A TALENs containing either canonical or engineered Q7 C-terminal 
domains with EL/KK FokI domains. Error bars reflect s.d. from three biological replicates, 
except two replicates for C4. All pairwise P-values were calculated between the cleavage 
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efficiencies of the on-target sequence (OnC) digested by CCR5A TALENs containing the 
canonical C-terminal vs. the cleavage efficiencies of a mutant sequence (C1, C2, …., or C8) 
digested by CCR5A TALENs containing the canonical C-terminal domain. All pairwise P-
values were also calculated between the cleavage efficiencies of the on-target sequence 
(OnC) digested by CCR5A TALENs containing the Q7 C-terminal domain vs. the cleavage 
efficiencies of a mutant sequence (C1, C2, …., or C8) digested by CCR5A TALENs 
containing the Q7 C-terminal domain. The cleavage efficiencies of mutant sequences C1, 
C2, C6, C7 and C8 digested by CCR5A TALENs containing the canonical C-terminal 
domain demonstrate a P-value significantly different (P-value < 0.025) from the cleavage 
efficiencies of the on-target sequence (OnC) digested by CCR5A TALENs containing the 
canonical C-terminal domain. The cleavage efficiencies of mutant sequences C1, C3, C4, 
C6, C7 and C8 digested by CCR5A TALENs containing the Q7 C-terminal domain 
demonstrate a P-value significantly different (P-value < 0.025) from the cleavage 
efficiencies of the on-target sequence (OnC) digested by CCR5A TALENs containing the 
Q7 C-terminal domain. (F) Same as (E) for ATM TALENs. The cleavage efficiencies of 
mutant sequences A1, A2, A3, A5, A6, A7 and A8 digested by ATM TALENs containing 
the Q7 C-terminal domain demonstrate a P-value significantly different (P-value < 0.025) 
from the cleavage efficiencies of ATM TALENs containing the canonical C-terminal 
domain digestion of the on-target sequence (OnC).
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Figure 6. Specificity of engineered TALENs in human cells
(A) The cellular modification efficiency of canonical and engineered TALENs expressed as 
a percentage of indels consistent with TALEN-induced modification out of total sequences 
is shown for the on-target CCR5A site (OnCCR5A) and for CCR5A off-target site #5 
(OffC5), the most highly cleaved off-target substrate tested. All pairwise P-values 
comparing the number of observed sequences containing insertions or deletions consistent 
with TALEN-induced cleavage vs. the total number of sequences were calculated with a 
Fischer exact test between samples (see Supplementary Table S7). P-values are < 0.005 for 
samples of canonical vs. Q3 vs. Q7 TALENs in the same FokI background for both on-
target and off-target sites with the exception of off-target site #5 modified with Q3 vs. Q7 
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TALENs in the EL/KK FokI background (P-value < 0.087). On:off target activity, defined 
as the ratio of on-target to off-target modification, is shown above each pair of bars. (B) The 
on:off target activity of the canonical, Q3, and Q7 TALENs for each detected genomic off-
target substrate of the CCR5A TALEN with the ELD/KKR FokI domain are shown. The 
absolute genomic modification frequency for the on-target site is in parentheses. (C) Same 
as (B) for the ATM TALENs and off-target sites. (D) The on:off target activities of the 
canonical, Q3, and Q7 TALENs for each detected genomic off-target substrate of the PMS2, 
SDHD, and HDAC1 TALENs with the ELD/KKR FokI domain are shown. The absolute 
genome modification frequency for the on-target site is in parentheses.
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